PTEN and TP53/p53 in endometrial carcinoma: molecular pathways, immunohistochemistry, molecular classification, and implications for resource-constrained African settings—a scoping review
Year: 2026
Type: article
Study design: Systematic Review
Abstract: Background Endometrial carcinoma (EC) is an important gynecological malignancy worldwide, but access to molecular profiling remains limited in resource-constrained settings. PTEN loss reflects disruption of PI3K/AKT/mTOR pathway regulation, whereas p53 immunohistochemistry (IHC) provides a surrogate assessment of p53 status within molecular classification. This scoping review maps their biological, diagnostic, clinicopathological and reported prognostic associations and considers implications for African settings. Methods The review followed the Arksey and O’Malley framework, refined by Levac et al., and reported according to PRISMA-ScR. PubMed/MEDLINE, Scopus, Web of Science, Google Scholar and African Journals OnLine were searched for English-language publications from 1 January 2001 to 8 August 2026. Eighteen primary studies were synthesized descriptively. We did not conduct a formal risk-of-bias assessment or certainty-of-evidence grading. Results Included studies reported associations of PTEN loss with endometrioid tumorigenesis and of molecularly detected TP53 alterations or abnormal p53 IHC patterns with adverse clinicopathological features and, in studies assessing clinical outcomes, adverse prognostic associations. African evidence comprised Nigerian p53 data, Kenyan combined PTEN/p53/MMR IHC findings, and South African MMR and molecular-classification studies. Complete molecular classification incorporates pathogenic POLE mutation status, MMR status and p53 status; PTEN is not classification-defining, but an adjunct biomarker pending further clinical validation. Conclusion p53 IHC contributes to molecular classification but cannot replace MMR or POLE assessment. PTEN remains an adjunctive biomarker in selected diagnostic and research contexts. An author-proposed phased framework prioritizes validated histopathology and MMR/p53 IHC, referral testing and integrated reporting. This framework has not been validated by the included studies; its clinical impact, cost-effectiveness, scalability and sustainability require prospective evaluation.
Source: Frontiers in Oncology
Authors: Juliet Oluchukwu Offor(Conceptualization, Investigation, Methodology, Resources, Writing – original draft, Writing – review & editing), Ayodele Omotoso(Methodology, Resources, Supervision, Validation, Writing – review & editing), Matthew Schlumbrecht(Supervision, Writing – review & editing), Sophia George(Supervision, Validation, Writing – review & editing)
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234466741
